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Abstract
Severe heart pathology upon virus infection is closely associated
with the immunological equipment of the host. Since there is no
specific treatment available, current research focuses on identify-
ing new drug targets to positively modulate predisposing immune
factors. Utilizing a murine model with high susceptibility to
coxsackievirus B3-induced myocarditis, this study describes ONX
0914—an immunoproteasome-specific inhibitor—as highly protec-
tive during severe heart disease. Represented by reduced heart
infiltration of monocytes/macrophages and diminished organ
damage, ONX 0914 treatment reversed fulminant pathology. Virus-
induced immune response features like overwhelming pro-
inflammatory cytokine and chemokine production as well as a
progressive loss of lymphocytes all being reminiscent of a sepsis-
like disease course were prevented by ONX 0914. Although the
viral burden was only minimally affected in highly susceptible
mice, resulting maintenance of immune homeostasis improved the
cardiac output, and saved animals from severe illness as well as
high mortality. Altogether, this could make ONX 0914 a potent
drug for the treatment of severe virus-mediated inflammation of
the heart and might rank immunoproteasome inhibitors among
drugs for preventing pathogen-induced immunopathology.
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Introduction
Myocarditis is an inflammatory condition of the heart most
commonly triggered through viral infection especially in young indi-
viduals (Epelman et al, 2015). But despite the fact that underlying
processes and mechanisms have been elucidated from different
angles by basic research for several decades, there is still no specific
treatment available. Further, it is unclear which circumstances
either prevent infected patients from clinical manifestation or
provoke severe pathology. The disease outcome may range from
subclinical disease to serious illness with acute heart failure and
sudden cardiac death and is mainly determined by an interplay
between virus-mediated cytotoxicity and the host’s immune
response (Cooper, 2009; Sagar et al, 2012). Besides other aspects,
the genetic background and associated with it the immunological
equipment of the host are thought to be predisposing factors for the
development of severe heart muscle inflammation. In this context,
scientific research utilized diverse inbred mouse strains to mirror
cardiac pathology in human patients (Corsten et al, 2012). Such
preclinical animal models are suited to investigate the efficacy of
novel immune-modulatory drug targets (Leuschner et al, 2015).
The proteasome—a multicatalytic protease essential for intracel-
lular protein degradation and viability of all mammalian cells—is
currently in the focus of research seeking new targets to treat cancer
and inflammatory illness (Groettrup et al, 2010; Basler et al, 2013).
First- and second-generation proteasome inhibitors, such as borte-
zomib and carfilzomib, are used for patients with multiple myeloma
(Richardson et al, 2003, 2005; Stewart et al, 2015). These inhibitors
target both major forms of the proteasome—the standard protea-
some of all somatic cells and the immunoproteasome mainly
expressed in cells of the immune system. The development of third-
generation inhibitors selective for the immunoproteasome has
opened up new opportunities not only for immunoproteasome
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research itself, but also for future clinical use. ONX 0914, originally
known as PR957, is such a potent inhibitor specific for the highly
active immunoproteasome subunit LMP7 (b5i; Muchamuel et al,
2009; Huber et al, 2012). Preclinical animal models utilizing this
compound demonstrated the therapeutic potential of selectively
targeting the immunoproteasome mainly for inflammatory disorders
(Muchamuel et al, 2009; Basler et al, 2010; Ichikawa et al, 2012).
Furthermore, the ONX 0914 analog KZR-616 has only recently
entered clinical development phase I/II trials treating patients with
autoimmune-triggered inflammation. These studies are based on the
highly regulated immunoproteasome function of controlling cyto-
kine production and antigen presentation (Muchamuel et al, 2009;
Basler et al, 2010, 2014; Groettrup et al, 2010; Kalim et al, 2012;
Mundt et al, 2016a), which is in turn intensively influenced through
its inhibition.
However, an anti-inflammatory potential of immunoproteasome
inhibition during infectious disease is still not characterized to the
same extent as it is for autoimmune disease. In addition to inducing
immunological protection from invading pathogens, infection can
also trigger overwhelming immune-pathological responses, leading
to destructive inflammation and organ damage. The importance of a
balanced immunoproteasome function in counteracting infection
and thereby influencing clinical signs and potentially disease
outcome has been shown for different pathogens by others (Tu
et al, 2009; Basler et al, 2011; Ersching et al, 2016; Mundt et al,
2016a,b) as well as for coxsackievirus B3 (CVB3)-mediated
myocarditis by our own group (Opitz et al, 2011; Paeschke et al,
2016). Further, the extent of inflammation during a suspected viral
myocarditis in patients is considered to be an independent negative
predictor of disease outcome (Kindermann et al, 2008). Since exces-
sive inflammation can be antagonized by selective immunoprotea-
some inhibition (Groettrup et al, 2010; Basler et al, 2013), this
study aimed to investigate the disease-modifying potential of the
third-generation inhibitor ONX 0914 during virus-induced myocardi-
tis. We addressed the questions to what extent ONX 0914 treatment
influences inflammation and disease outcome, and how this treat-
ment modulates the immune response after pathogen encounter.
Results
ONX-0914 treatment of C57BL/6 mice affects viral myocarditis
only mildly and results in intact activation of CVB3 adaptive
immune responses
Following up studies on previous work resolving proteasome biology
in C57BL/6 mice with hereditary low susceptibility to virus-induced
myocarditis (Jakel et al, 2009; Opitz et al, 2011; Rahnefeld et al,
2011; Ebstein et al, 2013), this mouse strain was treated with ONX
0914 and infected with a cardiotropic CVB3 variant. Since complete
selective inhibition of LMP7 subunits detected 3 h after ONX 0914
injection started to decline by 24 h post-treatment, ONX 0914 was
administered s.c. on a daily basis. Thereby, the as robust described
phenotype in terms of cardiac disease, mortality and overall condi-
tion was only mildly affected by ONX 0914 (Fig 1A and B). The day
8 p.i. status of virus-induced heart disease, which is in general a
rather mild one in C57BL/6 mice (B6), was mildly influenced by
ONX 0914, whereby the extent of myocardial injury represented by
the area of inflammation on heart tissue sections was increased
(Fig 1C). Further, the levels of pro-inflammatory cytokines/
chemokines in heart tissue were higher if affected at all compared to
vehicle-treated controls (Fig 1D). Consistent with mild increase in
myocardial injury, viral load of heart tissue was higher in ONX 0914-
treated mice (Fig 1E), which is most likely due to ONX 0914-induced
suppression of type I interferon (IFN) responses (Fig 1F). Impor-
tantly, ONX 0914-treated B6 mice were able to produce and maintain
CVB3-neutralizing antibodies levels as efficiently as their vehicle-
treated controls (Fig 1G). In turn, this surrogate finding reflects an
effective B and CD4+ T-cell activation upon viral infection even
under the influence of ONX 0914. In order to investigate whether the
development of an adequate immune memory status is established
unhindered as well, on day 28 after the initial virus infection, B6
mice were challenged a second time with CVB3. Fig 1H–J demon-
strates unequivocally that both test groups showed no visible or
measurable signs of re-infection. Mice were in overall good condition
mirrored by body weight status as a typical parameter of an ongoing
CVB3 infection (Fig 1H). Heart tissue was free of infectious virus
particles on day 8 after challenge (Fig 1I). Furthermore, no signs of
heart muscle damage or immune cell re-infiltration were found in
vehicle—as well as ONX 0914-treated B6 mice (Fig 1J).
High susceptibility to virus-induced myocarditis in A/J mice is
inverted by ONX 0914 treatment leading to preservation of
cardiac output
As a next step, we investigated the impact of an ONX 0914 treat-
ment in a highly susceptible host. In clear contrast to B6 mice, A/J
mice represent the group of human patients predisposed for the
development of severe acute viral cardiomyopathy (Chow et al,
1991; Klingel et al, 1992). While 60% of CVB3-infected vehicle-
treated mice had succumbed by day 7 p.i., ONX 0914 treatment
saved mice from severe illness and elevated survival rate up to
100% again (Fig 2A and B). In line with this, analysis of heart tissue
obtained from animals sacrificed 8-day p.i. revealed distinct
differences. Histological and more clearly immunohistochemical
staining of heart tissue (Fig 2C) and the following quantitative
evaluation of Mac-3-positive-stained area (Fig 2D) demonstrated a
profound myocarditis in vehicle-treated A/J mice and in contrast to
that only moderate signs of inflammation after inhibitor treatment.
Consistent with previous findings (Opitz et al, 2011; Rahnefeld
et al, 2014), Mac-3-positive signals were highly abundant especially
within inflammatory foci during myocarditis and ONX 0914-induced
effects were most impressive for these signals (Fig 2C and D). In
addition, infiltrated immune cells of hearts from vehicle- and ONX
0914-treated mice were quantitatively analyzed by flow cytometry
revealing a significant reduction in infiltrating myeloid CD11b+
immune cells in general in ONX 0914-treated mice (Fig 2E) and thus
corroborating reduced inflammatory organ damage under ONX 0914
influence. Importantly, reversal of susceptibility to virus-induced
myocarditis by ONX 0914 was reflected by detection of additional
signs of reduced immune-mediated injury such as significantly
decreased expression levels of the T-cell effector molecules gran-
zyme A, perforin-1, and IFN-c in heart tissue (Fig 2F). Also, the
overall abundance of cell death was reduced by ONX 0914 as indi-
cated by detection of lower viability dye signal intensity in non-
immune cells by flow cytometry analysis of heart tissue (Fig 2G).
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ONX 0914 effects on cardiac performance were assessed by
echocardiography during the inflammatory peak of viral myocarditis
(Table 1). In vehicle-treated, infected A/J mice, the cardiac output
was severely suppressed in comparison with baseline measurements
[baseline: 9.9  0.6 ml/min vs. 8-day p.i.: 5.3  0.5 ml/min
(P < 0.05)]. Diminished stroke volume was attributed to significant
disturbances of diastolic filling as indicated by reduction in diastolic
volume and increased isovolumic relaxation time, but not connected
to changes in ejection fraction. Consistent with its protective
immune-modulatory effects, ONX 0914 treatment impressively
reversed the impaired diastolic filling found in vehicle-treated mice.
Most strikingly, in comparison with vehicle treatment, cardiac
output was significantly higher under ONX 0914 influence (ONX
0914: 7.7  0.6 ml/min vs. vehicle: 5.3  0.5 ml/min [P < 0.05])
and not remarkably affected by CVB3 infection at all. Furthermore,
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vehicle treatment, ONX 0914 treatment led to intact diastolic filling
(ONX 0914: 36.2  1.9 ll vs. vehicle: 29.1  1.5 ll [P < 0.01])
yielding no significant deterioration during infection.
Since direct cytolysis of cardiomyocytes by the virus itself is
closely and causally connected with infiltration of immune cells
during acute state of myocarditis (Althof et al, 2014), next we investi-
gated whether ONX 0914-induced amelioration of myocardial injury
as shown in Fig 2 and reflected by improved cardiac output (Table 1)
might also involve alteration of the viral burden. Therefore, viral
titers of heart tissue usually peaking around 4–6 days after initial
virus inoculation (Opavsky et al, 2002) were determined throughout
disease course. We found reduced coxsackievirus genome and titers
under ONX 0914 influence shortly after virus inoculation (day 2 p.i.),
but at any point in time beyond infectious particles were not affected
by ONX 0914 (Fig 3A and B). Of note, ONX 0914 did not influence
the virus replication cycle directly (Fig EV1B). Since the pancreas
and not the heart is the primary organ in which CVB3 quickly repli-
cates to high titers (Klingel et al, 1992, 1996), we questioned whether
reduced viral burden 2 days after infection in heart tissue might be
attributed to an altered viral load in pancreas. We found no effect of
ONX 0914 treatment on pancreatic viral titers (Fig 3C). In contrast to
that and consistent with observations for heart tissue, the viral
burden was reduced on day 2 p.i. in spleen and serum as well (Fig 3D
and E). Altogether, these findings indicate that a temporarily reduced
viral burden in heart, spleen, and serum most likely reflects slightly
altered viremia, which in turn could be the result of a diminished
immune-mediated destruction of pancreatic tissue. And indeed, we
found altered signs of pancreas destruction such as reduced serum
lipase activity in ONX 0914-treated mice (Fig EV1B and C). Taken
together, since ONX 0914 had overall no effect on the viral burden in
heart and pancreas at the respective organ-specific peak of viral cyto-
toxicity, ONX 0914-induced protection from virus-induced pathology
in A/J mice appears not to be attributed to a major antiviral effect
and its positive sequels.
ONX 0914 influences lymphocyte abundance during
virus infection
We and others have demonstrated that high susceptibility to viral
myocarditis involves inefficient activation of type I IFN responses
(Wessely et al, 2001; Jakel et al, 2009; Rahnefeld et al, 2011, 2014;
Epelman et al, 2015). In line with this, we found IFN-b production in
CVB3-infected A/J mice to be severely impaired in general. ONX
0914 treatment exerted no significant additive detrimental effect on
systemic IFN-b production or tissue-resident type I IFN responses
(Fig EV3). In order to investigate, which immune factors might
contribute to ONX 0914-induced protection from virus-induced
immunopathology, we next elucidated the effect of ONX 0914 on the
immune cell equipment of the host during CVB3 infection. Immuno-
proteasome function is known to regulate lymphocyte survival,
proliferation, and differentiation as well as function (Fehling et al,
1994; Hensley et al, 2010; Moebius et al, 2010; Kalim et al, 2012) all
being closely connected to antigen presentation (Kincaid et al,
2012). Based on this, we first investigated the immune status mice
exhibit in terms of lymphocyte abundance, both right after ONX
0914 application and in addition after a longer period of inhibitor
exposure that corresponded to the time after CVB3 infection at which
myocarditis is fully developed. This allowed us to determine direct
ONX 0914-mediated effects apart from virus infection. Figure 4A and
B demonstrates significantly decreased numbers of splenic T
lymphocytes after single inhibitor treatment and a reduction in
splenic B-cell count after a 9-day treatment. Next, we analyzed blood
as well as the spleen as a representative lymphoid organ regarding
lymphocyte dissemination upon pathogen challenge. During CVB3
infection course, vehicle-treated A/J mice suffered a marked deple-
tion of lymphocytes in the periphery, which was completely
prevented under ONX 0914 influence (Fig 4C). Further, during early
stages of disease, spleens of compound-treated animals were popu-
lated by significantly more T lymphocytes compared to controls
(Fig 4D). Hence, the restrained lymphocyte depletion found in
infected, ONX 0914-treated mice at early stages of disease is most
likely not directly mediated by ONX 0914, but rather attributed to
secondary ONX 0914-mediated mechanisms of the systemic immune
response during infection. By day 8 p.i., T-cell count in spleen equal-
ized to comparable numbers in both vehicle- and ONX 0914-treated
mice. However, splenic B-cell numbers were slightly reduced under
inhibitor influence (Fig 4E). As B-cell function is indispensable for
humoral antiviral immunity during an infection with CVB3 (Mena
et al, 1999), we next investigated CVB3-neutralizing antibodies and
found increased titers under ONX 0914 influence 8-day p.i. (Fig 4F)
indicating intact or even improved activation of antiviral humoral
immunity in ONX 0914-treated A/J mice.
◀ Figure 1. Impact of ONX 0914 on CVB3 infection in C57BL/6 mice.A–F Starting one day prior to CVB3 (Nancy) inoculation, C57BL/6 mice were treated daily until day 10 p.i. with either ONX 0914 or vehicle and further three times a
week until day 28 p.i. Survival (A) as well as body weight (B) was monitored for 28 days. Average percentages of body weight loss relative to initial weight  SEM
are shown (vehicle n = 8, ONX 0914 n = 8). On day 8 p.i., where inflammation of the myocardium is expected to be fully developed, animals were sacrificed (C), and
heart tissue was analyzed. Paraffin-embedded heart sections were stained using hematoxylin and eosin. A representative image for each group is shown. Extent of
myocardial infiltration was scored microscopically, and percentage of inflamed area was assessed and calculated using ImageJ (vehicle n = 13, ONX 0914 n = 11).
Total heart tissue mRNA was isolated (D), reverse transcribed and cytokine/chemokine-specific gene expression was determined by TaqMan qPCR (vehicle n = 10,
ONX 0914 n = 10). Virus load (E) was determined by standard plaque assay assessing the amount of infectious virus particles (vehicle n = 13, ONX 0914 n = 10).
IFN-b serum levels (F) during early infection (day 2 p.i.) were determined by ELISA (control=uninfected animals, vehicle n = 7, ONX 0914 n = 7). CVB3-neutralizing
antibody titers in the serum (G) were determined after 8 and 28 days post CVB3 infection (day 8 vehicle n = 13, ONX 0914 n = 10, day 28 vehicle n = 8, ONX 0914
n = 7).
H–J To investigate the impact of ONX 0914 treatment on developing an immunological memory status, all mice were challenged with a second CVB3 infection on day
28 after the initial one. Animals received no further ONX 0914 treatment. Proportional body weight loss on day 8 after second challenge relative to the weight on
day 28 after the initial challenge (H). Viral load of heart tissue (I) was determined by plaque assay after 8 days. Additionally, paraffin-embedded heart tissue
sections were prepared and Masson’s trichrome staining was performed (J). Representative images for each group are shown (one experiment was carried out;
vehicle n = 8, ONX 0914 n = 6).
Data information: Data are mean  SEM. Scale bars, 60 lm. P-values are indicated in each graph. Survival curves were estimated from the Kaplan–Meier procedure
with the log-rank (Mantel–Cox). For body weight course, two-way ANOVA was used. Otherwise, unpaired t-test was conducted.
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ONX 0914 regulates dissemination and function of neutrophils
Although antiviral immune responses are dominated by lympho-
cytes, the innate immune system also plays a central role in the host
antiviral response helping to shape and control the ensuing adaptive
response (Jenne & Kubes, 2015). Hence, we investigated whether
abundance and function of innate immune cells might be influenced
by ONX 0914. We found that myeloid cells in general and neutro-
phils in particular were released from the bone marrow quickly after
ONX 0914 application. Dissemination resulted in higher numbers of
neutrophils in blood and spleen after a single ONX 0914 injection






Figure 2. Impact of ONX 0914 on CVB3 infection in A/J mice.
A–G A/J mice were infected with 104 PFU of CVB3 (Nancy). ONX 0914 or vehicle treatment was carried out daily, starting one day prior to virus inoculation. Proportional
survival of animals during the first 8 days of infection (A) was implemented into a Kaplan–Meier survival curve (E1 + E2; vehicle n = 12, ONX n = 12; log-rank
test). Body weight (B) was monitored for an 8-day period. For the indicated time points p.i., average percentage of weight loss relative to the initial value  SEM is
shown (E3; vehicle n = 15, ONX n = 15; two-way ANOVA test followed by Bonferroni multiple comparison). On day 8 p.i., animals were sacrificed and heart tissue
was analyzed. Paraffin-embedded tissue sections were prepared and differently stained (C). Upper row shows representative images for classical hematoxylin and
eosin staining. Middle and bottom row display images of immunohistochemical staining specific for either Mac3+ monocytes/macrophages or CD3+ T lymphocytes,
respectively (E1 + E2; vehicle n = 4, ONX n = 12). Scale bars, 60 lm. Additionally, proportional area infiltrated by Mac3+ monocytes/macrophages (D) was assessed
and calculated using ImageJ (means + SEM; E1 + E2; vehicle n = 4, ONX n = 12; unpaired t-test). Immune cells of the heart were stained with fluorochrome-
labeled antibodies (E). Number of CD11b+ myeloid cells per milligram heart tissue was determined by flow cytometry (means + SEM; E3; vehicle n = 3, ONX n = 8;
unpaired t-test). Further, total heart tissue mRNA (day 8 p.i.) was used to determine T-cell effector molecules (F) by TaqMan qPCR. Means of 2DCt + SEM are
shown (E1 + E2; vehicle n = 4, ONX n = 12; unpaired t-tests). Non-immune cells of the heart (CD45) (G) were stained with Fixable Viability Dye eFluor 780
(eBioscience), and mean fluorescence intensity (MFI) was determined by flow cytometry (means + SEM; E3; vehicle n = 3, ONX n = 8; unpaired t-test). P-values are
indicated in each graph.
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longer period of ONX 0914 treatment (Fig 5B). Upon CVB3 infec-
tion, ONX 0914-induced neutrophilia further increased in blood
(1- and 2-day p.i.). Control animals also reacted to virus infection
with a neutrophilia peaking around day 2 (Fig 5C). Further, ONX
0914 treatment during myocarditis leads to elevated neutrophil
counts in spleen tissue persisting at least until complete evolvement
of acute myocarditis (8-day p.i.; Fig 5D). In order to get a more elabo-
rated impression of how neutrophils become activated under the
influence of ONX 0914 treatment, we next analyzed the neutrophil
population regarding their expression level of activation markers.
CD18 (b2 integrin), as part of the ICAM-binding complex Mac-1, was
significantly upregulated, whereas CD62L expression was markedly
reduced upon ONX 0914 treatment, all being in line with an activa-
tion of neutrophils (Fig 5E). Also, ONX 0914 had a significantly posi-
tive impact on phagocytosis capacity of neutrophils (Fig 5F). Since
ONX 0914 treatment exerted such impressive effects on neutrophils,
we questioned whether these cells might be involved in the control
of CVB3. A unique neutrophil effector mechanism is the formation of
neutrophil extracellular traps (NETs). NETs are structures comprised
of a sticky, complex mesh of decondensed strands of nuclear DNA
released into the extracellular environment with protective for some
enveloped viruses (Jenne & Kubes, 2015). Hence, co-culture experi-
ments using NETs-forming neutrophils and CVB3 were conducted.
Figure 5G demonstrates that NET formation had no influence on the
resulting infection of NET-exposed CVB3 in HeLa cells as represented
by similar viral genome and capsid protein abundance as well as
unhindered formation of infectious CVB3 particles. To obtain a more
elaborate picture on the biological relevance of neutrophils during
CVB3 infection, we depleted these cells using a Ly6G-specific anti-
body in A/J mice. Upon CVB3 infection, neutrophil-depleted mice
were in an overall good condition regarding body weight loss and
survival. Most importantly, virus load, which was determined for
heart, pancreas, and spleen tissue after 2, 3, and 8 days, was found
to be within the same range as that of the respective control group
(Figs 5H and EV4). Altogether, these data suggest that neutrophil
function is most likely not essential for CVB3 control and indicate
that ONX 0914-induced neutrophilia is not decisive for protection
against immunopathology.
ONX 0914 regulates dissemination of monocytes/macrophages
Monocytes and macrophages, which are centrally involved in medi-
ating tissue damage and were reduced upon ONX 0914 treatment in
inflammatory heart disease (Fig 2), originate, like neutrophils, from
hematopoietic stem cells or subsequent progenitor stages. To inves-
tigate whether reduced infiltration into heart tissue may be the
result of altered mobilization of these cells, ONX 0914-induced
effects on the abundance of two different subsets of monocytes
expressing either high or low/medium levels of Ly6C as well as
macrophage counts were determined (Fig EV2). ONX 0914 treat-
ment increased especially the number of blood and splenic Ly6Chigh
inflammatory monocytes significantly (Fig 6A). Mononuclear
phagocytes as represented by macrophages might be derived from
inflammatory monocytes during infection (Ginhoux & Jung, 2014).
As demonstrated for neutrophils, ONX 0914 had a significantly posi-
tive impact on phagocytosis capacity of macrophages as well
(Fig 6B). As a next step, we investigated ONX 0914-induced effects
on monocytes/macrophages during infection and found a substan-
tially pronounced impact of the inhibitor. During the course of
CVB3 infection, ONX 0914 treatment led to elevated counts particu-
larly of monocytes in spleen tissue (Fig 6C) resulting in an
increased number of Ly6Chigh monocytes at the stage of complete
evolvement of acute myocarditis (8-day p.i.; Fig 6D). Taken
together, ONX 0914 mobilized monocytes from the bone marrow
during viral infection.
ONX 0914 treatment results in suppressed pro-inflammatory
cytokine/chemokine production during CVB3 infection
The demonstrated ONX 0914-mediated effects on the different
immune cell subsets during infection are indeed in agreement with
a functional activation of adaptive immune responses (Figs 1G–I
and 4F). However, these findings did not fully explain the improved
survival, attenuated heart inflammation, and maintained cardiac
output that we found in ONX 0914-treated mice. Pro-inflammatory
cytokine and chemokine are critical mediators that regulate migra-
tion and infiltration of immune cells. Moreover, for most of these
molecules, experimental evidence illustrates a disease-modifying
function during myocarditis (Corsten et al, 2012). Hence, next we
focused on the impact of ONX 0914 treatment on the production of
central inflammatory mediators like TNF-a, IL-6, IL-1b, MCP-1,
IP-10, and MIP-2a during disease. Despite increased infiltration of








CO [ml/min] 9.9  0.6 5.3  0.5 8.8  0.6 7.7  0.6a
Vol-d [ll] 42.4  1.4 29.1  1.5 38.7  1.4 36.2  1.9a
Vol-s [ll] 19.7  0.8 14.3  1.1 17.2  1.1 19.3  1.2a
SV [ll] 22.7  1.2 14.9  1.0 22.0  1.3 16.9  1.0
LVEF 53.2  1.8 51.6  2.5 54.8  2.5 46.7  1.5
LV-d [mm] 3.6  0.1 3.3  0.1 3.5  0.1 3.3  0.1
LV-s [mm] 2.6  0.1 2.5  0.1 2.5  0.1 2.7  0.1
IVRT [ms] 16.9  0.6 20.4  0.7 16.6  0.6 16.4  0.7a
MVdecel [ms] 23.5  1.0 31.7  1.5 27.4  1.3 22.7  1.4a
Heart rate
[bpm]
435  12 352  20 399  8 446  17a
CO, cardiac output; Vol-d, end-diastolic volume; Vol-s, end-systolic volume;
SV, stroke volume; LVEF, left ventricular ejection fraction; LV-d, left ventricle
internal diameter at diastole; LV-s, left ventricle internal diameter at systole;
IVRT, isovolumic relaxation time; MVdecel, deceleration time (IVRT, MVdecel
were determined by pulse-wave Doppler at mitral valve); bpm, beats per
minute.
Cardiac function at baseline was assessed by echocardiography directly prior
to the second ONX 0914 injection in A/J mice (baseline). The measurement
was followed by CVB3 inoculation on the same day. Mice were allocated to
respective groups: vehicle n = 15; ONX 0914 n = 15. On day 8 p.i.,
echocardiography was repeated (vehicle n = 14; ONX 0914 n = 14 mice).
Data are mean values  SEM. Repeated measurements two-way ANOVA was
performed followed by a Sidak’s multiple comparison test.
aSignificant differences (P < 0.05) between vehicle and ONX 0914-treated
mice at day 8 after infection as determined by post hoc analysis. There were
no significant differences between vehicle and ONX 0914-treated mice at
baseline.
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myeloid cells that majorly contribute to cytokine production into
splenic tissue, the expression of respective pro-inflammatory cytoki-
nes/chemokines was suppressed under ONX 0914 influence
(Fig 7A). This anti-inflammatory activity upon immunoproteasome
inhibition was corroborated by detection of significantly reduced
systemic amounts of TNF-a, IL-6, IL-1b, MCP-1, and MIP-2a in ONX
0914-treated mice 3 days after virus inoculation, respectively
(Fig 7B). Further, also at the stage of fully evolved inflammation of
heart tissue (day 8), the local expression of the respective cytoki-
nes/chemokines was substantially reduced by ONX 0914 (Fig 7C).
The overwhelming cytokine response which infected vehicle-treated
mice developed is in accordance with impaired diastolic filling,
high-grade infiltration, reduction in the cardiac output as well as
high mortality and overall reminiscent of a distributive shock condi-
tion in this group.
Since ONX 0914-induced suppression of cytokine/chemokine
production was identified as a major effector of overall diminished
pathology, we focused on this aspect in more detail. Thereby, exper-
imentally bone marrow-derived macrophages (BMM) were chal-
lenged with artificial single-stranded RNA—a Toll-like receptor 7
(TLR7) agonist—mirroring natural conditions under which intracel-
lular coxsackievirus RNA genomes serve as pathogen-associated
molecular patterns (PAMPs) and induce strong cytokine expression
in monocytes/macrophages provided by the bone marrow in
response to virus encounter. TLR7-activated BMM responded with
increased TNF-a, IL-1b, IL-6, MCP-1, IP-10, and MIP-2a production
(Fig 8). TLR7-engagement allows binding between TLR7 and
MyD88, which then induces mitogen-activated protein kinase
(MAPkinase) signaling (Blasius & Beutler, 2010). We investigated
whether MAPkinases might be involved and initially used specific
inhibitors of the three major MAPkinases EKR1/2, p38, and JNK to
elucidate a putative contribution of the respective kinases to TLR7-
induced cytokine/chemokine production. Fig 8A illustrates a role of
MAPkinase activation particularly for IL-6 and IL-1b production.
Moreover, we found that SP600125, which interferes with JNK/p38
phosphorylation, also reduced TNF-a expression and MIP-2a expres-
sion (Fig 8A). Next, we questioned whether as observed for spleen
and heart tissue during infection, ONX 0914 treatment influences
cytokine/chemokine production also in TLR7-activated BMM. We
found a profoundly suppressed cytokine/chemokine mRNA induc-
tion in cells that had been treated with ONX 0914 (Fig 8B). Since
MAPkinases were indeed involved in TLR7-dependent cytokine
induction and ONX 0914 negatively influenced TLR7-induced
responses, we pursued the hypothesis that ONX 0914 affects MAPki-
nase activation upon TLR7 engagement. In fact, under the influence
of ONX 0914, the abundance of the respective phosphorylated
kinases p-p38, p-ERK1/2, and p-JNK was significantly reduced in
TLR7 agonist-treated cells (Fig 8C and D). From these experiments,
we conclude that PAMP-induced activation (ssRNA) of respective
pattern recognition receptors (PRRs) (TLR7) and thereby affected





Figure 3. Viral burden during course of CVB3 infection in ONX 0914-treated A/J mice.
A–E A/J mice were infected with 104 PFU CVB3 (Nancy). ONX 0914 or vehicle treatment was carried out daily, starting one day prior to virus inoculation. Animals
were sacrificed at the indicated time p.i.: Heart tissue, pancreas, and spleen were isolated, and serum obtained. Viral load was determined by standard plaque
assay (A, C–E) assessing the amount of infectious virus particles as well as by TaqMan qPCR (B), detecting CVB3 genome copy levels in total myocardial RNA
(day 8 p.i.: E1 + E2; vehicle n = 4, ONX n = 12). Transformed means  SEM are presented. Unpaired t-tests were performed. P-values are indicated in each
graph.
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Discussion
To improve clinical outcome and potentially prevent heart failure
or even sudden death in hosts exhibiting high susceptibility to
developing severe acute and chronic heart pathology upon
pathogen encounter, new therapeutic approaches are in dire need.
Predominantly severe inflammation of infected heart tissue is
related to poor outcome in patients with suspected virus-induced
myocarditis (Kindermann et al, 2008). Based on that, we consid-
ered an approach to antagonize adverse immune response
activation by inhibiting immunoproteasome function utilizing the
ONX 0914 compound (Muchamuel et al, 2009). The present study
revealed ONX 0914 treatment as utmost protective during virus-
induced heart disease in mice leading to maintained survival and
improved hemodynamic performance. The course of acute ONX
0914-influenced myocarditis was strongly attenuated and charac-
terized by significantly reduced pro-inflammatory cytokine/chemo-
kine expression, less infiltration, and reduced heart tissue damage.
Our study underlines the substantial contribution of immunopro-
teasome proteolysis to stimulate an overwhelming myocardial
A B C
D E F
Figure 4. Abundance and distribution of lymphocytes under the influence of ONX 0914 and during CVB3 infection.
A, B Naive A/J mice were treated solely with ONX 0914 or vehicle for either a short time (18 h; light blue vs. white bars) (A) or long term (daily for 9 days; dark blue vs.
gray bars) (B). Subsequently, spleen was isolated and analyzed using flow cytometry. Plotted are means of total numbers of the indicated lymphoid (sub-)
populations + SEM (1–2 separate experiments were carried out; 18 h: vehicle n = 2–3, ONX n = 2–3; d8: vehicle n = 4, ONX n = 6). Unpaired t-tests were
performed. P-values are indicated in each graph.
C–F Starting one day prior to CVB3 infection, A/J mice were treated daily with either ONX 0914 or vehicle. At the indicated days after infection, mice were sacrificed,
blood (C) (seven separate experiments were carried out; vehicle n = 3–9, ONX n = 3–7) and spleen (D, E) (1(E)–2(D) separate experiments were carried out; d2: vehicle
n = 6, ONX n = 6; d8: E3 vehicle n = 3, ONX n = 8) were isolated, and the number of lymphocytes in general or of the indicated lymphocyte subsets was
determined by either automatic complete blood count analysis (C) or flow cytometry (D), respectively. CVB3-neutralizing antibody titers in the serum (F) were
determined after 8 days (E3: vehicle n = 10, ONX n = 15). Means  SEM are shown, and unpaired t-test was performed. P-values are indicated in each graph.
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immune response upon virus encounter eventually leading to
sudden death and congestive heart failure. Based on this study
and our previous work (Szalay et al, 2006; Jakel et al, 2009; Opitz
et al, 2011), we suggest that in immune-genetically predisposed
individuals, immunoproteasome activity is directly connected with
adverse clinical outcome during virus-mediated inflammatory heart
disease, and thus, immunoproteasome function represents a
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In contrast to former studies using germline LMP7-deficient
mouse models, in which lack of immunoproteasome function is at
least partially compensated by increased standard proteasome
formation (Opitz et al, 2011), ONX-0914 treatment predominantly
blocks LMP7-mediated protein hydrolysis (Muchamuel et al, 2009;
Huber et al, 2012). Most of our knowledge on the biological value
of the superior peptide hydrolysis capacity of the immunoprotea-
some in comparison with the standard proteasome originates from
studies that had been conducted in LMP7-deficient mice being on a
C57BL/6 background. Mice of this as resistant deemed genetic back-
ground (Chow et al, 1991) reflect a patient population, where no
treatment would need to be initiated after pathogen encounter of the
heart. In such mice, immunoproteasome formation especially after
cytokine stimulus is known to be involved in maintaining protein
homeostasis by degrading damaged proteins (Seifert et al, 2010;
Opitz et al, 2011; Ebstein et al, 2013). This is in clear contrast to the
picture observed in A/J mice exhibiting high susceptibility to virus-
mediated inflammation (Chow et al, 1991; Opavsky et al, 2002). In
this host, disturbances of immune homeostasis also involved imbal-
anced proteostasis as indicated by increased abundance of ubiquiti-
nated conjugates in heart tissue sections (Fig EV5). Suppression of
immunopathology achieved by immunoproteasome inhibition ulti-
mately also influenced proteostasis in this host.
Another major physiologically relevant function of immunopro-
teasomes found during viral infection is a more efficient generation
of viral peptides resulting in improved antigen presentation of MHC
class I epitopes (Schwarz et al, 2000; Kincaid et al, 2012). Although
facilitated antigen processing by the immunoproteasome is also
evident for coxsackievirus peptides in vitro (Jakel et al, 2009; Voigt
et al, 2010; Respondek et al, 2017), this immunoproteasome-depen-
dent improvement of epitope liberation has no effect on the course
of CVB3 infection in vivo (Opitz et al, 2011). Interestingly as shown
in this study, ONX 0914 treatment in C57BL/6 mice with hereditary
resistance to viral cardiomyopathy slightly deteriorated disease
parameters like viral load without affecting overall long-term
course. Such effects could be at least partially attributed to the solid
T1IFN response this host induces to combat CVB3 infection (Jakel
et al, 2009; Rahnefeld et al, 2011), and which was significantly
reduced after ONX 0914 application being in line with previous find-
ings by others (Muchamuel et al, 2009; Ichikawa et al, 2012).
Importantly, in C57BL/6 mice, no significant impact on induction of
an efficient specific immune response regarding formation of CVB3-
neutralizing antibodies could be observed. Intact activation of adap-
tive immunity with firm memory protection from viral heart disease
represents important safety prerequisites of ONX 0914 regarding its
putative clinical application.
Mouse models representing high susceptibility to viral myocardi-
tis demonstrated a shifted and overall significantly impaired T1IFN
response (Fig EV3; Jakel et al, 2009), and in case of A/J mice used
in this study, increased mortality and sepsis-like disease course of
CVB3 infection. The question arose how ONX 0914 treatment exerts
the demonstrated remarkably beneficial effect on disease and even
on mortality in this host. In addition to exocrine pancreatic tissue,
cardiotropic viruses like CVB3 directly destroy cardiomyocytes, and
this virus-mediated tissue destruction stimulates immune cell infil-
tration (Corsten et al, 2012; Rahnefeld et al, 2014). Particularly, the
recognition of viral pathogen motifs—like single-stranded RNA in
the case of CVB3—by the host’s PRR initiates the expression of
inflammatory cytokines/chemokines (Mann, 2011). Since we
observed substantial reduction in these immune active molecules
under ONX 0914 influence in A/J mice, we analyzed whether an
altered myocardial viral burden might be involved in this decreased
heart tissue inflammation. The local viral burden was slightly
reduced 2 days after infection in the heart. However, with ongoing
infection myocardial levels of infectious virus particles of both treat-
ment groups converged. Yet, ONX 0914-induced immune-modula-
tion was pronounced throughout disease course and particularly
significant even though cardiac pathology was fully defined 8 days
◀ Figure 5. Impact of ONX 0914-induced neutrophilia during CVB3 infection.A, B Naive A/J mice were treated solely with ONX 0914 or vehicle for either a short time (18 h; light blue vs. white bars/dots) or long term (daily for 9 days; dark blue vs.
gray bars). Subsequently, blood and spleen were isolated and analyzed for neutrophil abundance using flow cytometry. Plotted are means of total
neutrophils + SEM. Unpaired t-tests (+ Welch correction) were performed (1 (B) or 7 (A) separate experiments were carried out; vehicle n = 4–10, ONX n = 4–7).
C, D Next, A/J mice were infected with CVB3. ONX 0914 or vehicle treatment was carried out daily, starting one day prior to virus inoculation. At the indicated days after
infection, mice were sacrificed, blood (C) (7 separate experiments were carried out; vehicle n = 3–9, ONX n = 3–7) and spleen (D) (1(day 8)–4(day 3) separate
experiments were carried out, respectively; d3: vehicle n = 9–12, ONX n = 10–12; d8: E3 vehicle n = 3, ONX n = 8) were isolated, and the number of different
myeloid cell types was determined by either automatic complete blood count analysis or flow cytometry, respectively. Means + SEM are shown and unpaired
t-tests (+ Welch correction) were performed.
E After a single ONX 0914 injection into naive A/J mice, CD11b+/Ly6G+ splenic neutrophils were further characterized by assessing MFI for the surface markers CD18
and CD62L. Fold change of MFI relative to vehicle controls + SEM is shown, and unpaired t-tests were performed (two separate experiments were carried out;
vehicle n = 7, ONX n = 7).
F Splenocytes from ONX 0914- or vehicle-treated mice were first labeled with fluorochrome-conjugated antibodies against CD11b and Ly6G. To visualize and
monitor phagocytosis, cells were incubated with fluorophore-labeled particles for the indicated time and analyzed using flow cytometry. After gating on CD11b+/
Ly6G+ neutrophils, amount of phagocytosed-labeled particles was determined by assessing MFI per 105 cells. Means  SEM are depicted (one representative
experiment out of two is shown; vehicle n = 4, ONX n = 4; two-way ANOVA followed by Bonferroni’s multiple comparisons test).
G Neutrophils were incubated with PMA to induce NETosis or DMSO as a control. Cells were simultaneously infected with CVB3 at the indicated MOIs. After 4 h, the
supernatant was transferred onto HeLa cells. After 6 hours, expression of viral protein 1 (VP1) was analyzed by Western blotting, viral RNA was quantified by
TaqMan qPCR, and infectious progeny formation was determined by a plaque reduction assay. Western blot: one representative experiment is demonstrated; a
total of n = 1 for MOI 0.01 and MOI 0.1 as well as n = 2 separate experiments were conducted for MOI 1, respectively).
H Male A/J mice were treated with anti-Ly6G or isotype control antibody one day prior to infection. For a day 8 infection experiment, antibody injection was repeated
on day 3 p.i. and for a day 3 experiment on day 1 p.i. Mice were inoculated with a viral dose of 3.3 × 103 PFU to ensure survival of infected mice. Peripheral
neutrophil abundance was determined by automatic blood counting after a total of two Ly6G injections (day 1 and day 1 p.i.) on day 3 p.i. Viral load in heart
tissue was determined by standard plaque assay (one experiment for each time point (isotype n = 4, 5, 10, anti-Ly6G n = 3, 5, 6 for day 2, 3 and 8 respectively, t-test
for cell count and two-way ANOVA for CVB3 titer)). Transformed means + SEM are presented.
Data information: P-values are indicated in each graph where applicable.
Source data are available online for this figure.
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after virus inoculation. Therefore, we concluded that ONX 0914-
induced impact on cytokine production is independent from the
establishment of virus infection in a particular organ and most likely
involves other mechanisms.
Since the unimpaired effectiveness of innate immune mecha-
nisms and the closely connected resulting adaptive immune status of
the host are immensely crucial for disease outcome (Epelman et al,
2015), we characterized the existing immune status during CVB3
infection and the potential immune-modulating influence, ONX 0914
might exert, explaining the improved signs of disease. Being present
already prior as well as during virus infection, ONX 0914 directly
influenced neutrophils, which are the first and most abundant cell
population of the host’s innate immune response (Jenne & Kubes,
2015). Not only abundance was significantly increased in blood and
A B
C D
Figure 6. Impact of ONX 0914 on abundance and dissemination of monocytes/macrophages during CVB3 infection.
A, B Naive A/J mice were treated solely with ONX 0914 or vehicle daily for 9 days (A) (dark blue vs. gray bars) or with a single shot (B) (18 h; light blue vs. white
bars/dots). Subsequently, blood and spleen (A) were isolated and analyzed using flow cytometry. Plotted are means of total numbers of the indicated myeloid
(sub-)populations + SEM. Unpaired t-tests (+ Welch correction) were performed (one experiment; vehicle n = 4, ONX n = 6). Splenocytes from ONX 0914- or
vehicle-treated mice were first labeled with fluorochrome-conjugated antibodies against the surface markers CD11b and F4/80 (B). To visualize and monitor
phagocytosis, cells were incubated with fluorophore-labeled particles for the indicated time and analyzed using flow cytometry. After gating CD11b+/F4/80+
macrophages, amount of phagocytosed labeled particles was determined by MFI per 105 cells (means + SEM) (one representative experiment out of two is shown;
vehicle n = 4, ONX n = 4; two-way ANOVA followed by Bonferroni’s multiple comparisons test). P-values are indicated in each graph.
C, D A/J mice were infected with CVB3. ONX 0914 or vehicle treatment was carried out daily, starting one day prior to virus inoculation. 3 (C) and 8 days (D) after
infection, mice were sacrificed, spleen was isolated (1 (D) or 4 (C) separate experiments were carried out, respectively; d3: vehicle n = 9–12, ONX n = 10–12; d8: E3
vehicle n = 3, ONX n = 8), and the number of different myeloid cell types was determined by flow cytometry. A detailed description of the gating strategy for
identification of the different immune cell type is provided in Fig EV2. Means + SEM are shown, and unpaired t-tests (+ Welch correction) were performed.
P-values are indicated in each graph.
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in spleen. Neutrophils were also set into an advanced activated state.
Although the function of neutrophils in antiviral defense is not fully
resolved, several publications reported neutrophil recruitment in
virus infection being an actual part of a protective strategy, orches-
trated by the innate immune system leading to protective defense
against viral disease (Jenne & Kubes, 2015). Therefore, it seemed
likely that ONX 0914-induced neutrophilia could also influence
CVB3. Nevertheless, NET formation, which is considered a powerful
property of neutrophils to combat also viruses (Saitoh et al, 2012;
Jenne et al, 2013), did not influence CVB3. More supportive
evidence on the biological function of neutrophils in the battle
against CVB3 was obtained in vivo. Since neutrophil depletion had
no significant impact on CVB3-induced pathology, we concluded—
that consistent with a previous report on unaltered CVB3-induced
pathology in granulocyte-colony-stimulating factor (G-CSF)-treated
mice (Hiraoka et al, 1995)—ONX 0914-induced neutrophilia most
likely does not majorly attribute to diminished immunopathology in
A/J mice. No significant difference was seen in the survival, cardiac
disease, or myocardial virus titers between the G-CSF and the control
groups. Nevertheless, the impressive mobilization and functional
activation of neutrophils which we achieved by ONX 0914 treatment
independent of pathogen encounter are of high relevance for bacte-
ria-induced inflammatory syndromes with significant biological
impact of neutrophils.
In addition to neutrophils, ONX 0914 treatment also mobilized
monocytes/macrophages from the bone marrow leading to increased
numbers in blood and spleen. On the one hand, Ly6Chigh monocytes
are equipped with migration ability and represent immediate circu-
lating precursors for antigen-presenting dendritic cells (Ginhoux &
Jung, 2014). Having in mind that ONX 0914-treated A/J mice show
higher titers of CVB3-neutralizing antibodies, one might argue that
the significantly elevated numbers of those antigen-presenting
dendritic cell precursors could be as well involved in a more effective
onset of such an antiviral immune response. On the other hand and
decisive in our context, Ly6Chigh monocytes can give rise to macro-
phages under inflammatory conditions (Ginhoux & Jung, 2014). In
clear contrary to the observed enrichment of Ly6Chigh monocytes in
spleens of ONX-treated A/J mice, acute myocardial injury as
reflected by the extent of monocyte/macrophage infiltration and
accompanying pro-inflammatory cytokine response activation
(Corsten et al, 2012) was significantly reduced under ONX 0914
influence. This is of utmost importance in this context since the
peripheral abundance, for example, of inflammatory monocytes can
actually contribute to severe cardiac immunopathology (Leuschner
et al, 2015). Mononuclear phagocytes are responsible for removal of
cell remnants originating from infected and dying cells. Therefore, a
low abundant population might be beneficial for eliminating and
resolving inflammation (Corsten et al, 2012; Epelman et al, 2015).
In fact, we propose that immunoproteasome inhibitor treatment
might even facilitate this important function of macrophages since
we could clearly demonstrate a directly ONX 0914-mediated increase
in phagocytic capacity exerted by these cells.
A
B C
Figure 7. ONX 0914-mediated suppression of CVB3-induced pro-inflammatory cytokines/chemokines in A/J mice.
A–C A/J mice were infected with CVB3. ONX 0914 or vehicle treatment was carried out daily, starting one day prior to virus inoculation. Animals were sacrificed after
3-day (A, B) and 8-day p.i. (C). Total spleen mRNA (A) was used to determine cytokine/chemokine-specific expression of the indicated genes by TaqMan qPCR.
Means of 2DCt + SEM are shown (vehicle n = 7, ONX n = 9, t-tests). Serum concentration of the indicated cytokines/chemokines (B) was assessed using bead-
based multiplex immunoassay or ELISA, respectively. Depicted are means + SEM (four separate experiments were carried out; vehicle n = 3–7, ONX n = 3–7, t-
tests). During the peak of heart muscle inflammation, total heart mRNA (C) was used to determine cytokine/chemokine-specific expression of the indicated genes
by TaqMan qPCR. Means of 2DCt + SEM are shown (E1 + E2; vehicle n = 4, ONX n = 12, t-tests). P-values are indicated in each graph.
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Nevertheless, the magnitude of immune response activation in
infected hearts determines disease outcome (Kindermann et al,
2008). Monocytes/macrophages do not only limit tissue injury, but
they are also increasing acute inflammatory and fibrotic tissue
damage (Hirasawa et al, 1996; Jaquenod De Giusti et al, 2015). The
main effector molecules that influence the migration and local acute
as well as chronic fibrotic injury are chemokines and pro-inflamma-
tory cytokines, respectively. In fact, for most of the ONX 0914-influ-
enced cytokines such as TNF-a, IL-6, and IL-1 previous studies have
convincingly demonstrated that their concentration as well as the
timing of their release determine how these immune-modulatory
molecules actually affect the outcome of virus-induced myocarditis,
whereby high cytokine levels result in more severe pathology
(Corsten et al, 2012). According to that, clinical studies reported on
the adverse effects of these mediators in humans suffering septic
shock revealing both a separate as well as synergistic cardio-depres-
sive effect of TNF-a and IL-1 (Kumar et al, 1996; Cain et al, 1999).
Therefore, the ONX 0914-mediated suppression of cytokine produc-
tion observed in this study is most likely a driving force for
improvement of cardiac condition and improved survival in A/J
mice. Moreover, ONX 0914 treatment of predisposed hosts during
acute state of virus infection might also beneficially affect long-term
A B
C D
Figure 8. ONX 0914 manipulates TLR7 signaling leading to reduced MAPkinase phosphorylation.
A Bone marrow-derived macrophages (BMM) from A/J mice were cultivated. Mitogen-activated protein kinase (MAPkinase) inhibitors were used to investigate the
contribution of p38-, ERK1/2-, and JNK-mediated signaling to cytokine/chemokine expression upon TLR7 engagement. Therefore, BMM were treated with the
MAPkinase inhibitors SB203580 (p38), PD98059 (ERK1/2), SP600125 (JNK), or DMSO (control), respectively, for one hour prior to R848 stimulation. After 8 h, mRNA
levels of the indicated genes were determined by TaqMan qPCR. Data represent fold change increased mRNA expression (DDCt normalized to stimulated DMSO
control) and are mean of three independent experiments. Paired t-tests (inhibitor versus DMSO) were performed.
B BMM from A/J mice were treated with ONX 0914 or DMSO prior to stimulation with the TLR7 agonist R848. After 8 h, cytokine and chemokine expression was
determined for the indicated genes by TaqMan qPCR. Data represent fold change increased mRNA expression (normalized to un-stimulated DMSO control) and are
mean of four independent experiments. Paired t-tests were performed.
C, D BMM from A/J mice were treated with ONX 0914 or DMSO prior to stimulation with R848 for the indicated points in time. Cytosolic protein extracts were
subjected to Western blot analysis for detection of the phosphorylation status of p38 (Thr180/Tyr182), ERK1/2 (Thr202/Tyr204) and JNK (Thr183/Tyr185) (C).
Antibodies directed against the respective total MAPkinases were used as respective loading control. The most intense phosphorylation status for all MAPkinases
was observed after 15-min TLR7 engagement. Signal intensity at this point in time was determined for DMSO- and ONX 0914-treated cells (D), and signals of
phosphorylated kinases were normalized to the respective non-phosphorylated protein. For three independent experiments, thereby obtained data of ONX 0914-
treated cells were normalized to respective DMSO controls and plotted bar graphs demonstrate mean of the respective phosphorylated MAPkinases (unpaired
t-test).
Data information: Data presented as mean  SEM. P-values are indicated in each graph.
Source data are available online for this figure.
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disease outcome since the extent of myeloid cell infiltration and
cytokine production also substantially influences the activation of
cardiac remodeling and chronic pathology (Corsten et al, 2012;
Rahnefeld et al, 2014; Epelman et al, 2015; Leuschner et al, 2015).
In previous attempts to profile the role of immunoproteasome
proteolysis for pro-inflammatory effector cascades, others and we
have reported on modified effector responses upon engagement of
TLRs, T-cell receptor, and TNF-a receptor, yet the underlying path-
ways were less well characterized. Nevertheless, there is consensus
that ONX 0914 does not directly influence canonical NFjB signaling
(Muchamuel et al, 2009; Paeschke et al, 2016; Bitzer et al, 2017).
Other than that and in line with TLR4-mediated pentraxin3 produc-
tion (Paeschke et al, 2016), we provided compelling evidence for
reduced ERK1/2, p38, and JNK phosphorylation in TLR7-activated
BMM upon ONX 0914 treatment. Others and we confirmed that
therein-affected downstream effector kinase activity is as well
involved in pro-inflammatory cytokine/chemokine production
(Ronkina et al, 2007). Hence, thereby affected pathways might also
contribute to the impressively reduced local and systemic cytokine
response we found under ONX 0914 influence in spleen, serum, and
heart tissue in A/J mice. This finding is even more impressive since
the abundance of monocytes/macrophages was increased in spleen
by ONX 0914 at the same point in time. Our previous studies have
demonstrated that, in comparison with its standard proteasome
counterpart, the immunoproteasome is equipped with a superior
peptide hydrolysis capacity (Jakel et al, 2009; Voigt et al, 2010;
Mishto et al, 2014). Hence, we propose that immunoproteasome
proteolysis modulates the abundance and/or activity of certain
kinases, phosphatases and/or regulatory proteins that are involved
in, for example, the complex MAPkinase signaling network. To
identify such affected proteins, a comprehensive system biology-
based approach is needed in the future.
Taken together, ONX 0914 potently inversed high susceptibility
to virus-mediated acute myocarditis primarily based on a local and
systemic suppression of pro-inflammatory cytokine/chemokine
production and resulting detrimental conditions. While destructive
immune responses were reduced, pathogen-directed immunity was
maintained or considerably improved. Resulting maintenance of
immune homeostasis reversed inflammatory heart tissue damage
and, most strikingly, preserved cardiac output and survival upon
pathogen encounter. These immune-modulatory features exerted by
ONX 0914 during the course of viral myocarditis kept the cardiac
output close to baseline level. Consequently, immunoproteasome-
specific inhibitors like ONX 0914 rank among novel drugs for the
treatment of severe acute myocarditis. Moreover, the utmost benefi-
cial immune-modulatory impact found upon immunoproteasome
inhibitor treatment of infected mice warrants further preclinical test-
ing of such compounds for systemic inflammatory response
syndromes and sepsis.
Materials and Methods
Animals, virus, and infection protocols
Original mating pairs of the two different wild-type mouse strains—
A/J and C57BL/6—were purchased from Harlan Winkelmann (A/J)
and Jackson Laboratory (C57BL/6). For E3 day 8 and neutrophils
depletion studies conducted in A/J mice, larger cohorts were
purchased from Harlan Winkelmann and allowed to settle for at
least 1 week prior to virus inoculation. With the exception of
E1 + E2 (mixed gender was used), male adult in-house bred animals
(6- to 8-week-old) were injected intraperitoneally (i.p.) with
104 PFU (A/J) and 105 PFU (C57BL/6) of a cardiotropic variant of
CVB3 Nancy strain (Klingel et al, 1992). Average weight of A/J mice
included in experiment E1 and E2 was vehicle 20.4 g  0.8; ONX
20.6 g  0.93. As a large percentage of vehicle-treated mice
succumbed to infection, for E3, slightly older and consequently
heavier mice were used: vehicle 23.0 g  0.3; ONX 23.7 g  0.4.
To analyze CVB3-induced immune memory status, re-infection
experiments were carried out in C57BL/6 mice. Therefore, mice
were initially inoculated with 106 PFU CVB3 and 28-day p.i. chal-
lenged a second time with 105 PFU CVB3. For neutrophil depletion,
mice were injected i.p. with 50 lg low-endotoxin acid-free (LEAF)
Ly6G antibody (clone 1A8) or respective IgG2a isotype control
(BioLegend) one day prior to infection. Antibody delivery was
repeated after 48 h for mice that were sacrificed 3-day p.i. or after
72 h for mice that were sacrificed 8-day p.i. This study was carried
out in accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the German animal welfare
act, which is based on the Directive of the European Parliament and
of the Council on the protection of animals used for scientific
purposes. The protocol was approved by the Committee on the
Ethics of Animal Experiments of Berlin State authorities (G0274/
13). All efforts were made to minimize suffering.
Echocardiography
For echocardiography, mice were anesthetized with 1.5–2% isoflu-
rane and kept warm on a heated platform. Temperature and ECG
were continuously monitored. Cardiac function and morphology
were assessed with a VisualSonics Vevo 770 High-Frequency Imag-
ing System using a high-resolution (RMV-707B; 15–45 MHz) trans-
ducer. Standard imaging planes, M-mode, and functional
calculations were obtained. Pulsed wave Doppler measurements
were acquired from a modified apical two-chamber view on the
mitral valve. The parasternal long-axis view of the left ventricle
(LV) was used to guide calculations of percentage fractional short-
ening, ventricular dimensions and volumes. M-mode echocardio-
graphic images were recorded at the level of the papillary muscles
from the parasternal short-axis view. All measurements were
performed by an experienced, blinded technician.
Cell culture
Cells of peripheral blood (PBC) were purified from whole blood,
either obtained from puncture of the Vena facialis or by heart punc-
ture. RBC lysis was performed 2–3 times in a row by incubating with
0.83% ammonium chloride (NH4Cl) for 3–5 min at room tempera-
ture. Splenocytes (SPC) were prepared by passing spleen tissue
through a 70-lm cell strainer (BD Bioscience). After a wash step with
1× PBS, RBC were lysed in one step as described for blood cells. All
cell types were recovered by centrifugation (10 min, 310 g), re-
suspended in FACS buffer, and chilled on ice until flow cytometry.
Mouse bone marrow cells were isolated from A/J mice and culti-
vated in the presence of RPMI medium supplemented with 30%
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L929 cell-conditioned medium as a source of granulocyte/macro-
phage colony-stimulating factor as previously described (Paeschke
et al, 2016). Cells were treated with 100 nM ONX 0914 or DMSO
(Paeschke et al, 2016), respectively, prior to stimulation with the
TLR7/8 agonist R848 (10 lg/ml, StemCell Technologies. Alterna-
tively, bone marrow-derived macrophages were treated with 75 lM
PD98059 (ERK1/2), 10 lM SB203580 (p38), and 25 lM SP600125
(JNK) [all compounds were purchased from Invivogen] for 1 h prior
to TLR7 activation.
Neutrophils were isolated from human peripheral blood according
to procedures outlined elsewhere (Brinkmann et al, 2010). Briefly,
neutrophils were separated from whole blood by density centrifuga-
tion using Histopaque-1119 (Sigma-Aldrich) followed by a Percoll-
gradient centrifugation (Santa Cruz Biotechnology). 5 × 105 neutro-
phils were seeded in RPMI medium supplemented with 2% human
serum albumin (Grifols), and cells were incubated at 37°C and 5%
CO2 for 1 h. Formation of neutrophil extracellular traps (NETs) was
induced by 100 nM phorbol 12-myristate 13-acetate (PMA, Calbio-
chem). NET formation was confirmed microscopically by Hoechst
staining after 4 h. In parallel, cells were infected with CVB3 Nancy at
MOI 0.01, 0.1, and 1.0. After 4 h, supernatants were transferred onto
confluent HeLa cells. Cells were incubated for 30 min at 37°C with
10-fold dilutions of CVB3-containing supernatants and directly over-
laid with agar-containing MEM. Two to three days later, cells were
stained with 0.025% neutral red/PBS and plaque-forming units
(PFU) were counted 3 h after staining. Furthermore, HeLa cells were
inoculated with virus containing supernatants and cells were washed
after 1 h with PBS. Six hours after inoculation, RNA and protein were
isolated, viral RNA was quantified by TaqMan qPCR, and viral
protein production was determined by VP1 Western blotting.
For in cellulo infection studies, primary embryonic cardiomy-
ocytes (CM) were obtained from C57BL/6 mice on embryonic day 14
and cultured as described elsewhere (Spur et al, 2016). ONX 0914 or
DMSO was applied to each well, and simultaneously cells were
infected with CVB3 at MOI 5. Infectious virus particles were allowed
to settle and attach to the cell surface for 1 h. Afterward, unbound
virions were removed and cell culture was supplied with virus-free
but ONX-0914- or DMSO-containing medium. Another 2 h later,
medium was aspirated once more and replaced by inhibitor-/DMSO-
free DMEM. At the indicated times p.i., cell culture wells were quick-
frozen, thawed again, and clear supernatant was analyzed for
concentration of infectious virus particles by TCID50 assay.
Proteasome inhibitor and treatment protocols
ONX 0914 is a cell-permeable b5i-/LMP7-selective inhibitor (ONYX/
Amgen, San Francisco, CA or Selleckchem, San Diego, CA). ONX
0914 was formulated in an aqueous solution of 10% (w/v) Capti-
solTM (Ligand Pharmaceuticals SanDiego, CA) and 10 mM sodium
citrate (pH 6). The solution was subcutaneously (s.c.) administered
to mice at a dose of 10 mg/kg in a volume of 200 ll. Control group
animals received matching amounts of Captisol–sodium citrate mix
(referred to as vehicle).
Histological images and analysis
Heart tissue of infected and differentially treated mice was isolated
and immediately fixed in Histofix (1× PBS, 4% RothTM Histofix)
over-night. Afterward, Histofix was replaced by 1 × PBS, tissue was
paraffin embedded, and sections were prepared. Histological stain-
ing with hematoxylin/eosin (H&E) or Masson’s trichrome staining
as well as immunohistochemistry for the detection of CD3+ T
lymphocytes and Mac3+ macrophages was carried out as described
elsewhere (Kindermann et al, 2008). Area of inflammation/Mac3+-
positive area of inflammation was assessed as described in reference
(Rahnefeld et al, 2014). ImageJ software was used.
Isolation of infiltrated immune cells from heart tissue
After extraction of whole blood, heart was flushed with 15 ml PBS,
removed, and washed again in PBS. An in terms of weight defined
amount of heart tissue was minced in RPMI 1640 medium
(Biochrom) containing 10% (v/v) fetal calf serum (FCS)
(Biochrom), 1% (v/v) penicillin/streptomycin (Pan Biotech),
30 mM HEPES, 0.1% (w/v) collagenase type 2 (Worthington), and
0.015% (w/v) DNase I (Sigma-Aldrich). Tissue digestion occurred
during incubation at 37°C for 30 min (shaking at 800 rpm). In order
to obtain single-cell status, 10 mM EDTA was added, and cells were
washed with PBS and were passed through a 70-lm cell strainer
(BD Bioscience). Cells were recovered by centrifugation (10 min,
310 g), re-suspended in FACS buffer, and chilled on ice until flow
cytometry.
Flow cytometry
Either equal numbers of cells (BMC, PBC, and SPC) or cells puri-
fied from 15 mg heart tissue were incubated (20 min at 4°C) in
FACS buffer (phosphate-buffered saline, 2% FCS, 2 mM EDTA)
containing an anti-mouse Fc receptor blocking reagent (1:50;
Miltenyi). Afterward, fluorochrome-conjugated antibodies against
various surface markers were added and incubated for at least
20 min at 4°C protected from light. The following anti-mouse anti-
bodies were purchased from BD Bioscience: B220 (PE; clone RA3-
6B2) (1:300), CD90.2/Thy-1.2 (PE; clone 53-2.1) (1:300), NK-T/NK
Cell Antigen (PE; clone U5A2-13) (1:300), TER-119 (PE; clone
TER-119) (1:300), CD11b (PE-CF594; clone M1/70) (1:300), CD4
(V500; clone RM4-5) (1:100), CD8a (Pacific BlueTM; clone 53.6.7)
(1:100), CD62L (PerCP Cy5.5; clone MEL-14) (1:300). Anti-mouse
CD49b (PE; clone DX5) (1:300) was purchased from eBioscience/
Affymetrix, and the following anti-mouse antibodies were obtained
from BioLegend: CD45.2 (Brilliant Violet 711TM; clone 104) (1:200),
Ly6G (PerCP/Cy5.5; clone 1A8) (1:400 or 1:600), Ly6C (Pacific
BlueTM; clone HK1.4) (1:200), CD11c (Brilliant Violet 510TM; clone
N418) (1:150), F4/80 (APC; clone BM8) (1:100), CD3 (PerCP/
Cy5.5; clone 145-2C11) (1:300), B220 (FITC; clone RA3-6B2)
(1:200), CD19 (APC; clone 6D5) (1:500), CD18 (FITC; clone M18/
2) (1:250). Anti-mouse CD4 (FITC; clone RM4-5) (1:200) was
purchased from ThermoFisher Scientific. After several wash steps
with FACS buffer (centrifugation: 3 min at 306 g), cells were re-
suspended in 200 ll of the Fixable Viability Dye eFluor 780 (eBio-
science), diluted 1:1,000 in PBS, and incubated for 30 min on ice
protected from light. After serial wash steps with PBS followed by
fixation in FACSFix (1× PBS, 2% RothTMHistofix), cells were
acquired either on an LSRII or a FACSCalibur (both BD
Bioscience). Data were analyzed using FlowJo v10.0 software
(Tree Star). In order to quantify total cell numbers in heart tissue,
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123count eBeads (eBioscience) were used according to manufac-
turer’s protocol. Reported numbers were normalized for the weight
of total hearts, yielding the number of respective cell fraction per
mg tissue.
ELISA and multiplex assay
IL-6 concentration in serum was determined using OptiEIA mouse
IL6 enzyme-linked immunosorbent assay (ELISA) Set purchased
from BD Biosciences. Levels of tumor necrosis factor a (TNF-a),
interleukin-1b (IL-1b), monocyte chemoattractant protein-1 (MCP-
1), and macrophage inflammatory protein (MIP-2) were assessed by
bead-based multiplex immunoassay using Bio-Plex ProTM Mouse
Cytokine Standard Plex (Bio-Rad) performed according to the proto-
cols provided by the manufacturer. IFN-b concentration in serum
was determined using a VerikineTM Mouse IFN-b ELISA Kit
purchased from PBL Assay Science.
RNA isolation and quantitative real-time PCR
RNA isolation, cDNA synthesis, and quantitative real-time PCR
were performed as described in publication (Paeschke et al, 2016).
Primers and probes for TaqMan PCR were purchased from Ther-
moFisher (TaqManTM Gene Expression Assays). mRNA expression
was normalized to the housekeeping gene hypoxanthine-guanine
phosphoribosyltransferase (HPRT) according to the DCt or DDCt
method.
Western blot analysis and antibodies
For analysis of Toll-like receptor 7 (TLR7) signaling, ONX 0914-
treated bone marrow-derived macrophages (100 nM, 16 h) or
DMSO-treated cells were followed for 5, 15, and 30 min. Cellular
protein extracts were separated from nuclear extracts according to
the manufacturer’s protocol of an Active MotifTM kit. Primary anti-
bodies used were as follows: phospho-p38 (Thr180/Tyr182)
(1:1,000), p38 (1:1,000), phospho-JNK (Thr183/Tyr185) (1:1,000),
JNK (1:1,000), phospho-ERK1/2 (Thr202/Tyr204) (1:1,000), ERK1/2
(1:1,000) (all Cell Signaling). The bound primary antibodies were
detected using IRDye800CW labeled goat anti-mouse (p-p38)
(1:10,000)/anti-rabbit (all remaining) (1:10,000) secondary antibod-
ies in conjunction with an Odyssey CLx infrared imaging system (Li-
Cor Biosciences).
Titration of virus in mouse tissue and neutralization test
The titer of infectious virus was determined by standard plaque
assays, performed on subconfluent GMK cell monolayers as previ-
ously described (Rahnefeld et al, 2014). To determine the relative
amount of CVB3-neutralizing antibodies, serum was diluted initially
1:10 and further serially 1:2 using DMEM. In quadruplicate, the dif-
ferent dilutions were mixed with an equal volume of medium
containing 100 TCID50 of CVB3 and were incubated for 1 h at 37°C,
95% humidified atmosphere, and 5% CO2. Afterward, 100 ll GMK
cell suspension was added to each dilution parallel and the test was
incubated for at least 4 days at 37°C/5% CO2. The dilution of serum,
which protected cells from virus infection completely, was set as
antibody titer.
Phagocytosis assay
The ability of splenic neutrophils and macrophages to phagocyte
was analyzed using pHrodoTM Green Escherichia coli BioParticlesTM
Conjugate for Phagocytosis (ThermoFisher) according to the manu-
facturer‘s instructions. To be able to gate on CD11b+/Ly6G+ or F4/
80+ populations, prior to administration, splenocytes were surface-
labeled as described. While probes were incubated for the indicated
time at 37°C/5% CO2, negative controls rested on ice. Phagocytosis
was stopped by placing the cells on ice. After one wash step, cells
were immediately analyzed by flow cytometry using a FACSCalibur
(BD Bioscience).
Statistics
Statistical analysis of the data was performed in GraphPad Prism
v6.00 or v7.00 for Windows (GraphPad Software, La Jolla, California,
USA). Data are given as mean /+ standard error of the mean (SEM)
unless specified otherwise. Logarithmic data (virus titer, semi-quanti-
tative RNA quantification) measured on a linear scale were trans-
formed logarithmically prior to data plotting and data analysis. Paired
or unpaired t-tests were used for two group comparisons. If samples
had unequal variances (determined by an F test), an unpaired
t-test with the Welch correction was used. For multiple-group
The paper explained
Problem
In genetically predisposed patients, viral infection of the heart muscle
can activate a devastating immune response, resulting in severe func-
tional impairment of the heart, chronic organ failure, or even sudden
death. We aimed to define a novel approach that targets adverse
immune response activation, but ensures efficient pathogen clearance.
Results
We utilized a compound that specifically targets a major catalytically
active subunit called LMP7 of a multicatalytic protease complex—the
immunoproteasome—virtually found in all human immune cells. ONX
0914 inhibits protein cleavage mediated by this subunit orthologue in
mice. When we treated mice with high hereditary susceptibility to
virus-mediated inflammation of the heart, we observed fundamental
beneficial effects. Administration of ONX 0914 antagonized detrimen-
tal immune response activation and efficiently suppressed the pro-
inflammatory cytokine storm that was characteristic and decisive for
mortality and cardiac dysfunction of vehicle-treated mice. Compound-
treated mice did not only survive, and they were in overall good
condition and demonstrated substantially reduced signs of inflamma-
tory heart tissue damage. We provided some molecular insights into
how immunoproteasome proteolysis might influence a complex
signaling immune network leading to overwhelming inflammation.
Strikingly, the inhibition of the immune cell resident protease ensured
pathogen elimination and proved to be safe also after long-term
application.
Impact
Immunoproteasome-specific inhibitors like ONX 0914 rank among
novel drugs for the treatment of severe virus-mediated inflammation
of the heart. The utmost beneficial immune-modulatory impact found
upon compound treatment during infection warrants further testing
for other sterile or pathogen-induced systemic inflammatory response
syndromes.
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comparisons, unequal-variance versions of ANOVA (one-way or two-
way ANOVA) were performed, followed by a Tukey’s multiple
comparison test with the exception that for repeated measurements
two-way ANOVA was followed by a Sidak’s multiple comparison
test. Survival curves were estimated from the Kaplan–Meier proce-
dure with the log-rank (Mantel–Cox) test to compare survival among
groups. All tests used were two-tailed. The significance threshold for
all tests was set at the 0.05 level.
Expanded View for this article is available online.
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